| Date |
Subject |
Media |
| 2025-09-08 |
Licensing Partner Expected to Announce Phase III Data for L606 in September–October; Pharmosa Biopharm Optimistic
|
Pharmosa Biopharm announced on the 13th that its licensing partner Liquidia Corporation (LQDA) plans to host an R&D Day in September–October this year to release the latest results from the open-label Phase III clinical trial of L606, an investigational therapy for pulmonary arterial hypertension (PAH, WHO Group I). The company expressed optimism about the upcoming milestone. |
| 2025-09-08 |
Heavy Ion Therapy for Pancreatic Cancer: Taipei Veterans General Hospital and NYU Langone Health Form Strategic Partnership for Patient Referral and Research
|
In a landmark Taiwan–U.S. medical collaboration, Taipei Veterans General Hospital (Taipei VGH) President Dr. Wei-Ming Chen led a delegation to visit NYU Langone Health, where both institutions signed a formal research agreement with a focus on pancreatic cancer treatment. The collaboration will prioritize heavy ion therapy, patient referral, and sharing of research outcomes. |
| 2025-09-08 |
United Orthopedic Reports Record July Revenue; H1 EPS NT$2.46, Japan and U.S. Drive Growth
|
United Orthopedic Corporation (UOC) announced its first-half financial results and July revenue performance. In the second quarter, exchange rate fluctuations and product mix impacted profitability, with both gross margin and operating margin declining by three percentage points from the prior quarter. Non-operating losses from foreign exchange further weighed on results, bringing quarterly net income after tax down to NT$46.57 million, or earnings per share (EPS) of NT$0.48. Cumulative EPS for the first half reached NT$2.46. |
| 2025-09-08 |
Medeon Biodesign’s Aortic Arch Repair Device Duett Receives FDA Approval for Phase II Clinical Trial
|
Medeon Biodesign announced yesterday that its subsidiary, Aquedeon Medical, Inc., has received approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase II clinical trial for Duett, its aortic arch repair device. Building on the 35 cases previously approved, the expanded study will now enroll between 72 and 90 patients. The trial aims to validate Duett’s clinical value at scale, marking another critical step toward securing FDA market clearance. |
| 2025-09-03 |
Taiwan Bio Therapeutics Acquires TRACT Therapeutics to Expand Transplant Rejection and Autoimmune Disease Markets
|
Taiwan Bio Therapeutics announced on the 13th that it has signed a merger agreement with its partner, TRACT Therapeutics, Inc. Through its wholly owned U.S. subsidiary, Taiwan Bio Holding LLC, the company will acquire 100% equity in TRACT for US$3.5 million in cash. The transaction will be completed following approval by relevant authorities, officially bringing TRACT under the Taiwan Bio Therapeutics Group. |
| 2025-09-03 |
Bora Pharmaceuticals Responds to Section 232 Tariffs with Two Strategies
|
Bora Pharmaceuticals announced at its investor conference on the 12th that it will adopt two strategies to counter potential Section 232 tariffs: a “manufactured-to-market” model and the establishment of an offshore capital pool (BlockGoogle). Chairman Bobby Sheng expressed optimism that operations in the second half of the year will outperform the first half. The company’s acquisition targets remain unchanged, with several promising prospects under evaluation, though developments under Trump’s administration are still being closely monitored. |
| 2025-09-03 |
General Biologicals Advances on Three Fronts with Multiple CLIA Reagents Securing TFDA Approval
|
General Biologicals announced that its chemiluminescence immunoassay (CLIA) technology platform is achieving successive milestones. Following the approval of its fully automated chemiluminescence immunoassay analyzer by Taiwan’s Food and Drug Administration (TFDA) for special medical device manufacturing and licensing, the company has now obtained five TFDA medical device licenses for CLIA reagents. An additional 20 reagent applications are currently under review. Several hospitals have already begun testing, and collaborations have been launched with three clinical laboratories in Taiwan, while discussions are ongoing with other hospitals and labs, helping to expand momentum in the precision medicine sector. |
| 2025-09-03 |
SunWay Biotech’s Probiotic Strain Receives U.S. FDA GRAS Certification, Opening Export Opportunities
|
SunWay Biotech announced that its best-selling probiotic strain, Lactobacillus paracasei NTU 101, has received the U.S. Food and Drug Administration (FDA) “Generally Recognized As Safe” (GRAS, GRN001232) certification. This milestone not only paves the way for SunWay to expand its export opportunities but also marks the first Lactobacillus paracasei strain in Taiwan to obtain this recognition, underscoring the company’s strong research capabilities and strategic business vision. |
| 2025-09-03 |
Pan-Chyr Yang, Chairman of DIAMOND BIOFUND: Unleashing Three Forces to Propel Taiwan’s Biotech Industry Globally
|
Pan-Chyr Yang, Chairman of DIAMOND BIOFUND, stated yesterday (11) that the global biotech sector is at a pivotal intersection of multiple innovations, including AI applications, precision medicine, and cell therapy. Taiwan, with its comprehensive clinical and translational capabilities, must accelerate the integration of R&D, capital, and international market access. He emphasized that through the combined forces of long-term funding, institutional design, and global alignment, Taiwan’s biotech industry can be guided toward global leadership. |
| 2025-09-03 |
Asia-Pacific Biotechnology Investment Forum Kicks Off Executive Yuan Secretary-General Ming-Hsin Kung: Three Key Strategies to Strengthen Global Links in Biotech Industry
|
The 2025 Asia-Pacific Biotechnology Investment Forum opened yesterday (11). Executive Yuan Secretary-General Ming-Hsin Kung emphasized that with the integration of AI, ICT industries, and clinical applications, Taiwan’s biotech sector is not merely focused on manufacturing medical products but is redefining the future of healthcare. The government will implement three key strategies: supporting the transformation and upgrading of traditional industries, encouraging innovative R&D, and accelerating market adoption while strengthening local supply chains to connect with global markets. |
